Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blisibimod in IgA Nephropathy
NCT02052219Phase 3Withdrawn
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Oct 2014
- Primary completion
- Oct 2016
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 3 trial of blisibimod in IgA nephropathy (IgAN), sponsored by Anthera Pharmaceuticals, Inc.. Planned start Oct 2014; status: withdrawn.
02
Drugs
blisibimod
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT02052219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052219.